rs200649500
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP4_StrongBP6
The NM_022124.6(CDH23):c.2239C>T(p.Arg747Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00202 in 1,613,720 control chromosomes in the GnomAD database, including 5 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. R747R) has been classified as Likely benign.
Frequency
Consequence
NM_022124.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CDH23 | NM_022124.6 | c.2239C>T | p.Arg747Cys | missense_variant | 21/70 | ENST00000224721.12 | |
CDH23 | NM_001171930.2 | c.2239C>T | p.Arg747Cys | missense_variant | 21/32 | ||
CDH23 | NM_001171931.2 | c.2239C>T | p.Arg747Cys | missense_variant | 21/26 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CDH23 | ENST00000224721.12 | c.2239C>T | p.Arg747Cys | missense_variant | 21/70 | 5 | NM_022124.6 | P1 |
Frequencies
GnomAD3 genomes ? AF: 0.00127 AC: 193AN: 152040Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00110 AC: 273AN: 248988Hom.: 1 AF XY: 0.00108 AC XY: 146AN XY: 135114
GnomAD4 exome AF: 0.00210 AC: 3065AN: 1461562Hom.: 5 Cov.: 32 AF XY: 0.00209 AC XY: 1523AN XY: 727060
GnomAD4 genome ? AF: 0.00127 AC: 193AN: 152158Hom.: 0 Cov.: 32 AF XY: 0.00106 AC XY: 79AN XY: 74378
ClinVar
Submissions by phenotype
not provided Uncertain:4Benign:4
Likely benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | Apr 16, 2019 | - - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Sep 25, 2020 | This variant is associated with the following publications: (PMID: 21436283, 24875298, 23804846) - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Oct 01, 2023 | CDH23: BS1:Supporting - |
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | May 12, 2017 | The p.Arg747Cys variant (rs200649500) has been previously identified in a hearing loss cohort (Shearer et al. 2013) but was not identified in a patient with 2nd pathogenic variant of CDH23. This variant has been reported to ClinVar (Variation ID: 45890). The p.Arg747Cys variant is listed in the NHLBI GO Exome Sequencing Project with an overall population frequency of 0.18 percent (identified on 22 out of 12,542 chromosomes) and is listed in the Genome Aggregation Database (gnomAD) with a European (Non-Finnish) population frequency of 0.20 percent (identified on 247 out of 126,652 chromosomes, including 1 homozygote). The arginine at position 747 is highly conserved, up to Zebrafish (considering 12 species) (Alamut v2.10) and computational analyses of the effects of the p.Arg747Cys variant on protein structure and function predict a deleterious effect (SIFT: damaging, MutationTaster: disease causing, PolyPhen-2: probably damaging). Altogether, there is not enough evidence to classify the p.Arg747Cys variant with certainty. - |
Uncertain significance, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The CDH23 p.Arg747Cys variant was identified in 1 of 260 proband chromosomes (frequency: 0.00385) from individuals with nonsyndromic hearing loss and was present in 1 of 18 control chromosomes (frequency: 0.056) from healthy individuals (Vona_2014_PMID:24875298; Shearer_2013_PMID:23804846). The variant was identified in dbSNP (ID: rs200649500) and ClinVar (classified as uncertain significance by Illumina and ARUP Laboratories, and as likely benign by Laboratory for Molecular Medicine). Laboratory for Molecular Medicine reported this variant in an individual with Usher syndrome who carried another pathogenic CDH23 variant in cis, as well as in other individuals with alternate explanations for their hearing loss. The variant was identified in control databases in 304 of 280334 chromosomes (1 homozygous) at a frequency of 0.001084 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: European (non-Finnish) in 255 of 128328 chromosomes (freq: 0.001987), Other in 6 of 7134 chromosomes (freq: 0.000841), African in 16 of 24150 chromosomes (freq: 0.000663), Latino in 16 of 35354 chromosomes (freq: 0.000453), South Asian in 7 of 30590 chromosomes (freq: 0.000229) and European (Finnish) in 4 of 24894 chromosomes (freq: 0.000161), but was not observed in the Ashkenazi Jewish or East Asian populations. The p.Arg747 residue is conserved across mammals and other organisms, and four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) suggest that the variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. - |
Likely benign, criteria provided, single submitter | clinical testing | Invitae | Feb 01, 2024 | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Pituitary adenoma 5, multiple types Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Sep 16, 2019 | This variant was classified as: Uncertain significance. The available evidence on this variant's pathogenicity is insufficient or conflicting. The following ACMG criteria were applied in classifying this variant: PP3. - |
Usher syndrome type 1 Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Apr 15, 2020 | - - |
Usher syndrome type 1D Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. - |
Autosomal recessive nonsyndromic hearing loss 12 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. - |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | May 18, 2017 | p.Arg747Cys in exon 21 of CDH23: This variant is not expected to have clinical s ignificance because it has been identified in 0.2% (247/126652) of European chro mosomes including one homozygote by the Genome Aggregation Database (gnomAD, htt p://gnomad.broadinstitute.org; dbSNP rs200649500). It has been observed in 4 ind ividuals with alternate explanations for their hearing loss (Roux 2011, LMM Data ), including 1 individual who had a pathogenic truncating CDH23 variant in cis w ith this variant (https://grenada.lumc.nl: Patient ID FR0145311510; Roux 2011). This variant has also been observed in 5 additional individuals with hearing los s; however, a variant affecting the remaining copy of CDH23 was not identified ( Shearer 2013, LMM Data). In summary, given its relatively high frequency in the general population, multiple reports of the variant in individuals with alterna te etiologies, its presence in cis with a pathogenic CDH23 variant, and the fact that it has never been observed in trans with a clearly pathogenic CDH23 varian t in affected individuals, this variant is likely benign. - |
CDH23-related disorder Benign:1
Likely benign, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Feb 21, 2024 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at